U.S. Markets close in 2 hrs 52 mins
  • S&P 500

    4,526.53
    -50.57 (-1.10%)
     
  • Dow 30

    34,524.90
    -114.89 (-0.33%)
     
  • Nasdaq

    15,032.10
    -349.22 (-2.27%)
     
  • Russell 2000

    2,164.00
    -42.33 (-1.92%)
     
  • Crude Oil

    66.83
    +0.33 (+0.50%)
     
  • Gold

    1,781.60
    +18.90 (+1.07%)
     
  • Silver

    22.42
    +0.14 (+0.61%)
     
  • EUR/USD

    1.1313
    +0.0008 (+0.0679%)
     
  • 10-Yr Bond

    1.3780
    -0.0700 (-4.83%)
     
  • Vix

    31.04
    +3.09 (+11.06%)
     
  • GBP/USD

    1.3237
    -0.0065 (-0.4911%)
     
  • USD/JPY

    112.8510
    -0.3580 (-0.3162%)
     
  • BTC-USD

    55,104.19
    -1,359.90 (-2.41%)
     
  • CMC Crypto 200

    1,397.69
    -44.07 (-3.06%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 85% On Their Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Abeona Therapeutics Inc. (NASDAQ:ABEO) shareholders will doubtless be very grateful to see the share price up 48% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churning. To wit, the share price sky-dived 85% in that time. So we're relieved for long term holders to see a bit of uplift. Only time will tell if the company can sustain the turnaround.

We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

See our latest analysis for Abeona Therapeutics

Abeona Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Over three years, Abeona Therapeutics grew revenue at 70% per year. That's well above most other pre-profit companies. So on the face of it we're really surprised to see the share price down 23% a year in the same time period. You'd want to take a close look at the balance sheet, as well as the losses. Sometimes fast revenue growth doesn't lead to profits. Unless the balance sheet is strong, the company might have to raise capital.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Abeona Therapeutics shareholders are up 31% for the year. But that return falls short of the market. But at least that's still a gain! Over five years the TSR has been a reduction of 4% per year, over five years. So this might be a sign the business has turned its fortunes around. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Abeona Therapeutics , and understanding them should be part of your investment process.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.